This article was highlighted for PRO subscribers, Seeking Alpha's service for professional investors. Find out how you can get the best content on Seeking Alpha here.
The ability of Provention Bio's (PRVB) lead drug candidate, teplizumab, to delay the onset and potentially prevent Type 1 diabetes (T1D) can change the lives of people pre-disposed to getting the disease. This drug candidate has potential to revolutionize T1D treatment, as it is the only therapy of its kind being prepared for FDA submission later this year. As we stated in our first article on